Do analysts rate NUWE or AMIX?

Autonomix Medical has a consensus price target of $42.00, suggesting a potential upside of 513.14%. Given Autonomix Medical's stronger consensus rating and higher possible upside, analysts plainly believe Autonomix Medical is more favorable than Nuwellis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuwellis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Autonomix Medical 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is NUWE or AMIX more profitable?

Autonomix Medical has a net margin of 0.00% compared to Nuwellis' net margin of -123.38%. Autonomix Medical's return on equity of -231.18% beat Nuwellis' return on equity. Company Net Margins Return on Equity Return on Assets Nuwellis -123.38% -362.89% -158.38% Autonomix Medical N/A -231.18% -187.69%

Does the media refer more to NUWE or AMIX?

In the previous week, Autonomix Medical had 1 more articles in the media than Nuwellis. MarketBeat recorded 8 mentions for Autonomix Medical and 7 mentions for Nuwellis. Autonomix Medical's average media sentiment score of 0.98 beat Nuwellis' score of -0.28 indicating that Autonomix Medical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuwellis 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Autonomix Medical 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend HSCS or NUWE?

HeartSciences currently has a consensus price target of $8.00, indicating a potential upside of 288.35%. Given HeartSciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe HeartSciences is more favorable than Nuwellis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HeartSciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Nuwellis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is HSCS or NUWE more profitable?

HeartSciences has a net margin of 0.00% compared to Nuwellis' net margin of -123.38%. HeartSciences' return on equity of -358.60% beat Nuwellis' return on equity. Company Net Margins Return on Equity Return on Assets HeartSciences N/A -358.60% -144.82% Nuwellis -123.38% -362.89% -158.38%

Do analysts recommend NUWE or NXL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuwellis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Nexalin Technology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is NUWE or NXL more profitable?

Nuwellis has a net margin of -123.38% compared to Nexalin Technology's net margin of -4,141.94%. Nexalin Technology's return on equity of -278.24% beat Nuwellis' return on equity. Company Net Margins Return on Equity Return on Assets Nuwellis -123.38% -362.89% -158.38% Nexalin Technology -4,141.94% -278.24% -218.42%

Do analysts prefer NUWE or NVNO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuwellis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 enVVeno Medical 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33

Which has better valuation and earnings, NUWE or NVNO?

Nuwellis has higher revenue and earnings than enVVeno Medical. enVVeno Medical is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nuwellis $8.27M 0.29 -$17.52M -$2.24 thousand N/A enVVeno Medical N/A N/A -$19.47M -$19.33 N/A

Is NUWE or NVNO more profitable?

enVVeno Medical has a net margin of 0.00% compared to Nuwellis' net margin of -123.38%. enVVeno Medical's return on equity of -62.28% beat Nuwellis' return on equity. Company Net Margins Return on Equity Return on Assets Nuwellis -123.38% -362.89% -158.38% enVVeno Medical N/A -62.28% -56.83%

Do analysts prefer NUWE or FEMY?

Femasys has a consensus target price of $56.67, suggesting a potential upside of 2,374.53%. Given Femasys' stronger consensus rating and higher probable upside, analysts plainly believe Femasys is more favorable than Nuwellis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuwellis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Femasys 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has better earnings and valuation, NUWE or FEMY?

Nuwellis has higher revenue and earnings than Femasys. Femasys is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nuwellis $8.27M 0.29 -$17.52M -$2.24 thousand N/A Femasys $2.29M 3.02 -$18.63M -$5.40 N/A

Is NUWE or FEMY more profitable?

Nuwellis has a net margin of -123.38% compared to Femasys' net margin of -521.97%. Femasys' return on equity of -258.08% beat Nuwellis' return on equity. Company Net Margins Return on Equity Return on Assets Nuwellis -123.38% -362.89% -158.38% Femasys -521.97% -258.08% -73.72%

Does the media favor NUWE or FEMY?

In the previous week, Femasys had 6 more articles in the media than Nuwellis. MarketBeat recorded 13 mentions for Femasys and 7 mentions for Nuwellis. Femasys' average media sentiment score of 1.10 beat Nuwellis' score of -0.28 indicating that Femasys is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuwellis 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Femasys 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Nuwellis (NUWE) Competitors

$1.31 +0.01 (+0.77%)

Closing price 04:00 PM Eastern

Extended Trading

$1.32 +0.01 (+0.46%)

As of 07:49 PM Eastern

Compare

NUWE vs. AMIX, HSCS, NXL, NVNO, and FEMY

Should you buy Nuwellis stock or one of its competitors? Nuwellis's main competitors and comparable companies include Autonomix Medical (AMIX), HeartSciences (HSCS), Nexalin Technology (NXL), enVVeno Medical (NVNO), and Femasys (FEMY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Nuwellis compare to Autonomix Medical?

Nuwellis (NASDAQ:NUWE) and Autonomix Medical (NASDAQ:AMIX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, risk, dividends, profitability, analyst recommendations, earnings and valuation.

Autonomix Medical has a net margin of 0.00% compared to Nuwellis' net margin of -123.38%. Autonomix Medical's return on equity of -231.18% beat Nuwellis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuwellis	-123.38%	-362.89%	-158.38%
Autonomix Medical	N/A	-231.18%	-187.69%

In the previous week, Autonomix Medical had 1 more articles in the media than Nuwellis. MarketBeat recorded 8 mentions for Autonomix Medical and 7 mentions for Nuwellis. Autonomix Medical's average media sentiment score of 0.98 beat Nuwellis' score of -0.28 indicating that Autonomix Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuwellis	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Autonomix Medical	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Autonomix Medical has lower revenue, but higher earnings than Nuwellis. Autonomix Medical is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuwellis	$8.27M	0.29	-$17.52M	-$2.24 thousand	N/A
Autonomix Medical	N/A	N/A	-$16.72M	-$74.58	N/A

3.1% of Nuwellis shares are owned by institutional investors. Comparatively, 10.8% of Autonomix Medical shares are owned by institutional investors. 1.6% of Nuwellis shares are owned by company insiders. Comparatively, 6.2% of Autonomix Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Autonomix Medical has a consensus price target of $42.00, suggesting a potential upside of 513.14%. Given Autonomix Medical's stronger consensus rating and higher possible upside, analysts plainly believe Autonomix Medical is more favorable than Nuwellis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuwellis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Autonomix Medical	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Nuwellis has a beta of 0.31, meaning that its share price is 69% less volatile than the broader market. Comparatively, Autonomix Medical has a beta of -1.17, meaning that its share price is 217% less volatile than the broader market.

Summary

Autonomix Medical beats Nuwellis on 11 of the 14 factors compared between the two stocks.

How does Nuwellis compare to HeartSciences?

HeartSciences (NASDAQ:HSCS) and Nuwellis (NASDAQ:NUWE) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, institutional ownership, valuation, earnings, risk, profitability and dividends.

In the previous week, Nuwellis had 6 more articles in the media than HeartSciences. MarketBeat recorded 7 mentions for Nuwellis and 1 mentions for HeartSciences. HeartSciences' average media sentiment score of 0.94 beat Nuwellis' score of -0.28 indicating that HeartSciences is being referred to more favorably in the media.

Company	Overall Sentiment
HeartSciences	Positive
Nuwellis	Neutral

HeartSciences has a net margin of 0.00% compared to Nuwellis' net margin of -123.38%. HeartSciences' return on equity of -358.60% beat Nuwellis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HeartSciences	N/A	-358.60%	-144.82%
Nuwellis	-123.38%	-362.89%	-158.38%

HeartSciences has higher earnings, but lower revenue than Nuwellis. HeartSciences is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HeartSciences	N/A	N/A	-$9.14M	-$3.94	N/A
Nuwellis	$8.27M	0.29	-$17.52M	-$2.24 thousand	N/A

HeartSciences has a beta of 1.79, indicating that its share price is 79% more volatile than the broader market. Comparatively, Nuwellis has a beta of 0.31, indicating that its share price is 69% less volatile than the broader market.

HeartSciences currently has a consensus price target of $8.00, indicating a potential upside of 288.35%. Given HeartSciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe HeartSciences is more favorable than Nuwellis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HeartSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Nuwellis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

17.2% of HeartSciences shares are owned by institutional investors. Comparatively, 3.1% of Nuwellis shares are owned by institutional investors. 4.9% of HeartSciences shares are owned by insiders. Comparatively, 1.6% of Nuwellis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

HeartSciences beats Nuwellis on 12 of the 15 factors compared between the two stocks.

How does Nuwellis compare to Nexalin Technology?

Nuwellis (NASDAQ:NUWE) and Nexalin Technology (NASDAQ:NXL) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, media sentiment, analyst recommendations, earnings and institutional ownership.

Nuwellis has a net margin of -123.38% compared to Nexalin Technology's net margin of -4,141.94%. Nexalin Technology's return on equity of -278.24% beat Nuwellis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuwellis	-123.38%	-362.89%	-158.38%
Nexalin Technology	-4,141.94%	-278.24%	-218.42%

Nuwellis has a beta of 0.31, indicating that its share price is 69% less volatile than the broader market. Comparatively, Nexalin Technology has a beta of 4, indicating that its share price is 300% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuwellis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Nexalin Technology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Nexalin Technology has lower revenue, but higher earnings than Nuwellis. Nexalin Technology is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuwellis	$8.27M	0.29	-$17.52M	-$2.24 thousand	N/A
Nexalin Technology	$300K	25.71	-$8.22M	-$0.47	N/A

3.1% of Nuwellis shares are held by institutional investors. Comparatively, 0.7% of Nexalin Technology shares are held by institutional investors. 1.6% of Nuwellis shares are held by insiders. Comparatively, 16.9% of Nexalin Technology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Nuwellis had 4 more articles in the media than Nexalin Technology. MarketBeat recorded 7 mentions for Nuwellis and 3 mentions for Nexalin Technology. Nexalin Technology's average media sentiment score of -0.04 beat Nuwellis' score of -0.28 indicating that Nexalin Technology is being referred to more favorably in the news media.

Company	Overall Sentiment
Nuwellis	Neutral
Nexalin Technology	Neutral

Summary

Nexalin Technology beats Nuwellis on 7 of the 13 factors compared between the two stocks.

How does Nuwellis compare to enVVeno Medical?

Nuwellis (NASDAQ:NUWE) and enVVeno Medical (NASDAQ:NVNO) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, risk, institutional ownership, profitability, valuation and earnings.

In the previous week, Nuwellis had 5 more articles in the media than enVVeno Medical. MarketBeat recorded 7 mentions for Nuwellis and 2 mentions for enVVeno Medical. enVVeno Medical's average media sentiment score of 0.43 beat Nuwellis' score of -0.28 indicating that enVVeno Medical is being referred to more favorably in the news media.

Company	Overall Sentiment
Nuwellis	Neutral
enVVeno Medical	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuwellis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
enVVeno Medical	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

enVVeno Medical has a net margin of 0.00% compared to Nuwellis' net margin of -123.38%. enVVeno Medical's return on equity of -62.28% beat Nuwellis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuwellis	-123.38%	-362.89%	-158.38%
enVVeno Medical	N/A	-62.28%	-56.83%

3.1% of Nuwellis shares are owned by institutional investors. Comparatively, 34.7% of enVVeno Medical shares are owned by institutional investors. 1.6% of Nuwellis shares are owned by company insiders. Comparatively, 15.0% of enVVeno Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Nuwellis has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market. Comparatively, enVVeno Medical has a beta of 1.1, suggesting that its share price is 10% more volatile than the broader market.

Nuwellis has higher revenue and earnings than enVVeno Medical. enVVeno Medical is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuwellis	$8.27M	0.29	-$17.52M	-$2.24 thousand	N/A
enVVeno Medical	N/A	N/A	-$19.47M	-$19.33	N/A

Summary

enVVeno Medical beats Nuwellis on 10 of the 14 factors compared between the two stocks.

How does Nuwellis compare to Femasys?

Nuwellis (NASDAQ:NUWE) and Femasys (NASDAQ:FEMY) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

3.1% of Nuwellis shares are held by institutional investors. Comparatively, 65.3% of Femasys shares are held by institutional investors. 1.6% of Nuwellis shares are held by company insiders. Comparatively, 7.8% of Femasys shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Nuwellis has higher revenue and earnings than Femasys. Femasys is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuwellis	$8.27M	0.29	-$17.52M	-$2.24 thousand	N/A
Femasys	$2.29M	3.02	-$18.63M	-$5.40	N/A

Femasys has a consensus target price of $56.67, suggesting a potential upside of 2,374.53%. Given Femasys' stronger consensus rating and higher probable upside, analysts plainly believe Femasys is more favorable than Nuwellis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuwellis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Femasys	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Nuwellis has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market. Comparatively, Femasys has a beta of -2.08, suggesting that its share price is 308% less volatile than the broader market.

In the previous week, Femasys had 6 more articles in the media than Nuwellis. MarketBeat recorded 13 mentions for Femasys and 7 mentions for Nuwellis. Femasys' average media sentiment score of 1.10 beat Nuwellis' score of -0.28 indicating that Femasys is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuwellis	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Femasys	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nuwellis has a net margin of -123.38% compared to Femasys' net margin of -521.97%. Femasys' return on equity of -258.08% beat Nuwellis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuwellis	-123.38%	-362.89%	-158.38%
Femasys	-521.97%	-258.08%	-73.72%

Summary

Femasys beats Nuwellis on 11 of the 16 factors compared between the two stocks.

Get Nuwellis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NUWE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NUWE vs. The Competition

Export

Metric	Nuwellis	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.42M	$5.95B	$7.06B	$13.10B
Dividend Yield	N/A	1.76%	2.57%	10.45%
P/E Ratio	-0.01	21.85	211.09	21.74
Price / Sales	0.29	63.14	602.98	92.99
Price / Cash	N/A	33.92	70.48	50.90
Price / Book	0.02	6.10	12.91	6.24
Net Income	-$17.52M	$148.67M	$3.45B	$347.60M
7 Day Performance	-12.08%	1.84%	1.12%	1.07%
1 Month Performance	-59.32%	4.56%	1.79%	1.03%
1 Year Performance	-99.34%	8.67%	67.69%	20.77%

Nuwellis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NUWE Nuwellis	0.2274 of 5 stars	$1.31 +0.8%	N/A	-99.3%	$2.42M	$8.27M	N/A	70	News Coverage Earnings Report Short Interest Increase
AMIX Autonomix Medical	3.0073 of 5 stars	$7.53 -17.4%	$42.00 +457.8%	-70.6%	$8.86M	N/A	N/A	1	Earnings Report Short Interest Increase
HSCS HeartSciences	2.6624 of 5 stars	$2.00 -2.4%	$8.00 +300.0%	-41.3%	$7.99M	$4.32K	N/A	10
NXL Nexalin Technology	0.5043 of 5 stars	$0.36 -0.7%	N/A	-58.2%	$7.88M	$275.58K	N/A	3	Positive News Earnings Report Short Interest Decrease
NVNO enVVeno Medical	1.5357 of 5 stars	$10.99 -1.3%	N/A	-93.4%	$7.60M	N/A	N/A	30	Short Interest Increase Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NUWE) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nuwellis (NUWE) Competitors

NUWE vs. AMIX, HSCS, NXL, NVNO, and FEMY

How does Nuwellis compare to Autonomix Medical?

Summary

How does Nuwellis compare to HeartSciences?

Summary

How does Nuwellis compare to Nexalin Technology?

Summary

How does Nuwellis compare to enVVeno Medical?

Summary

How does Nuwellis compare to Femasys?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NUWE vs. The Competition

Nuwellis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nuwellis (NUWE) Competitors

NUWE vs. AMIX, HSCS, NXL, NVNO, and FEMY

How does Nuwellis compare to Autonomix Medical?

Is NUWE or AMIX more profitable?

Does the media refer more to NUWE or AMIX?

Which has stronger valuation & earnings, NUWE or AMIX?

Do institutionals & insiders hold more shares of NUWE or AMIX?

Do analysts rate NUWE or AMIX?

Which has more risk & volatility, NUWE or AMIX?

Summary

How does Nuwellis compare to HeartSciences?

Does the media prefer HSCS or NUWE?

Is HSCS or NUWE more profitable?

Which has stronger valuation and earnings, HSCS or NUWE?

Which has more volatility & risk, HSCS or NUWE?

Do analysts recommend HSCS or NUWE?

Do institutionals and insiders believe in HSCS or NUWE?

Summary

How does Nuwellis compare to Nexalin Technology?

Is NUWE or NXL more profitable?

Which has more risk and volatility, NUWE or NXL?

Do analysts recommend NUWE or NXL?

Which has stronger valuation & earnings, NUWE or NXL?

Do insiders and institutionals hold more shares of NUWE or NXL?

Does the media favor NUWE or NXL?

Summary

How does Nuwellis compare to enVVeno Medical?

Does the media favor NUWE or NVNO?

Do analysts prefer NUWE or NVNO?

Is NUWE or NVNO more profitable?

Do institutionals & insiders have more ownership in NUWE or NVNO?

Which has more risk and volatility, NUWE or NVNO?

Which has better valuation and earnings, NUWE or NVNO?

Summary

How does Nuwellis compare to Femasys?

Do insiders & institutionals hold more shares of NUWE or FEMY?

Which has better earnings and valuation, NUWE or FEMY?

Do analysts prefer NUWE or FEMY?

Which has more volatility and risk, NUWE or FEMY?

Does the media favor NUWE or FEMY?

Is NUWE or FEMY more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NUWE vs. The Competition

Nuwellis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools